2Q22 Results

#TodoCuidadoAoCuidar

Retail Gross

Revenue

R$ 965M (+25.9%)

Group Gross

Revenue

R$ 1,058M (+26.7%)

HIGHLIGHTS

2Q22

Retail Gross

Adjusted

Market

Margin

EBITDA

Share

31.1% (+0.9 p.p.)

R$ 56M (+40.7%)

+ 0,4 p.p.

Margin of 5.3%

(vs 2Q21)

Digital

Stores opening

NPS

15.7% of Sales

+ 17 New stores

80

(+24.1% vs 2Q21)

2

CONSISTENT GROWTH

Evolution - Retail Gross Revenue

R$ 3.174

R$ 2.692

CAGR

R$ 2.541

R$ 2.252

+22.6%

2Q19/2Q22

16.8%

R$ 2.058

R$ 1.819

R$ 1.843

CAGR 14%

R$ 1.558

R$ 1.503

R$ 1.368

CAGR

R$ 1.217

R$ 1.040

1H19/1H22

R$ 874

15.5%

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

1H21

1H22

3

RETAIL GROSS REVENUE WITH EXCELLENT PERFORMANCE VS 2Q21, ON A

STRONG COMPARISON BASIS

Sales Growth - Retail

Panvel's sale grows 25.9% in 2Q22

(R$ millions)

Gross Revenue - Retail

883.9

877.4

965.4

766.8

787.9

2Q21

3Q21

4Q21

1Q22

2Q22

28.9%

25.9%

18.1%

19.3%

14.3%

2Q21

3Q21

4Q21

1Q22

2Q22

Panvel Average Sale - Southern Region

Growth 2Q22 vs 2Q21

Average sale

Panvel 2Q22

12.9%

R$ 598k

6.5%

4.1%

Panvel

Abrafarma

Chains

Fonte: IQVIA

4

MSSS AND SSS SHOW ROBUST GROWTH AND ABOVE INFLATION IN 2Q22

Same Stores Growth

19.9%

19.2%

10.6%

11.8%

8.4%

2Q21

3Q21

4Q21

1Q22

2Q22

MSSS GROWS 15.8% IN THE

QUARTER

  1. GROWS 19.2% IN THE QUARTER

Mature Stores Growth

16.7%

15.8%

10.3%

7.9%

6.4%

2Q21

3Q21

4Q21

1Q22

2Q22

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Dimed SA Distribuidora de Medicamentos published this content on 11 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2022 15:26:03 UTC.